Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Investor Presentation (November 2019)
15 slides from Arbutus Biopharma's investor presentation, Nov 6, 2019
Slide 1: Singularly Focused on HBV
Singularly Focused on HBV November 2019 NASDAQ: ABUS www.arbutusbio.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements that are not historical facts are hereby identified as forward-looking statements for this pur
Slide 3: Investment Highlights
Investment Highlights Singular therapeutic focus - curing chronic Hepatitis B Virus (HBV) Team with Significant antiviral Broad Financial Goal unmet medical expertise & HBV Position Functional need in HBV proven track Portfolio Cure record Global HBV Applying HBV assets $90.1M cash at 9/30/19 Goal o
Slide 4: Proven Leadership Team
Proven Leadership Team William H. Collier Michael J. Sofia, PhD Gaston Picchio, PhD Successful track records President and CEO Chief Scientific Officer Chief Development Officer in both the discovery, development, and commercialization of multiple antivirals: sofosbuvir, etravirine, rilpivirine, tel
Slide 5: HBV Lifecycle Illustrates Key Points for Intervention
HBV Lifecycle Illustrates Key Points for Intervention A combination of agents with complementary MOA is needed to cure HBV 1 –Nucleoside Analogue 2 –Capsid Inhibitor 3 –AB-729 3 –RNA Destabilizer 2 3 1 2 NASDAQ: ABUS www.arbutusbio.com
Slide 6: Keys to Therapeutic Success
1 Reduce/Suppress Keys to Viral DNA & Antigens Therapeutic Block Replication . NA . Capsid Inhibitor Success . RNAi . RNA Destabilizer Block HBsAg . RNAi Suppress HBV DNA . RNA Destabilizer Reduce cccDNA Pool and viral antigens . Capsid Inhibitor Leading to an Reawaken host HBV CURE immune response
Slide 7: Arbutus HBV Pipeline
Arbutus HBV Pipeline Phase I Candidate Lead Op IND Enabling Healthy Subjects HBV Subjects Phase II Selection HBsAg Reduction RNAi AB-729 AB-452 HBV RNA Destabilizers 2nd Gen HBV DNA Suppression AB-506 Development discontinued Capsid Inhibitors 3rd gen Immune Reawakening PD-L1 1st gen NASDAQ: ABUS ww
Slide 8: Capsid Inhibitor: Blocking HBV Replication
Reduce/Suppress Capsid Viral DNA & Antigens Inhibitor: Blocking HBV HBV Replication HBsAg Replication cccDNA Pool Driving HBV DNA to undetectable, in the serum and Reduced HBsAg in the liver is a key to therapeutic Immuno-modulation success in HBV Reawaken/Boost Host Immune Response NASDAQ: ABUS www
Slide 9: Next Generation Capsid Inhibitor
Next Generation Next generation compound to be selected for IND-enabling studies by Capsid December 2019 Inhibitor Novel chemical series differentiated from AB-506 and other competitor compounds in the Class II capsid inhibitor space Leverages a novel binding site within the core protein dimer-dimer
Slide 10: Driving Down HBsAg Is Key to HBV Therapeutic Success
Reduce/Suppress Driving Viral DNA & Antigens Down HBsAg Is A Key to HBV Replication HBsAg Therapeutic cccDNA Pool Success in HBV HBsAg is responsible for immune exhaustion Reduced HBsAg Replication inhibitors do not block HBsAg production Immuno-modulation Reawaken/Boost Host Immune Response NASDAQ:
Slide 11: AB-729 RNAi Therapeutic
AB-729 RNAi Single trigger RNAi agent targeting all HBV transcripts Therapeutic Inhibits HBV replication and lowers all HBV antigens . Potent HBsAg reduction in preclinical models Pan-genotypic activity across HBV genotypes Proprietary GalNAc-conjugate delivery technology provides Duration of HBsAg
Slide 12: AB-729 In Vivo Single Dose Response & Duration
AB-729 In Vivo Single 4 Dose Response 3 Saline & Duration 1 mg/kg 2 3 mg/kg 9 mg/kg Clear dose response Mean (n=5) ± SD 1 in AAV mouse model (Log IU/mL) Serum HBsAg Serum Achieves maximum HBsAg reduction possible 0 in this model LLOQ -1 Duration supports 0 2 4 6 8 10 a clinical dosing frequency 1 do
Slide 13: Small Molecule HBV RNA Destabilizers
Small Molecule HBV RNA Destabilizers HBV RNA reduction leads to interference in viral gene AAV mouse model expression, DNA replication, and virion assembly PO dosing 100 10 (% Baseline) Serum HBsAg Serum Dose-dependent reduction in HBsAg 1 0 1 2 3 4 5 6 7 Study Day HBsAg reduction correlates with 12
Slide 14: AB-452 and RNA Destabilizer Program
AB-452 and RNA Destabilizer Program Multiple evaluations underway to support AB-452 and RNA destabilizer program next steps Completed Ongoing IND enabling studies and . In vitro target engagement 28 day toxicology and target-based cell viability evaluations Multiple AB-452 mechanism of action st
Slide 15: Arbutus HBV Pipeline
Arbutus HBV Pipeline Phase I Candidate Lead Op IND Enabling Healthy Subjects HBV Subjects Phase II Selection HBsAg Reduction RNAi AB-729 AB-452 HBV RNA Destabilizers 2nd Gen HBV DNA Suppression AB-506 Development discontinued Capsid Inhibitors 3rd gen Immune Reawakening PD-L1 1st gen NASDAQ: ABUS ww
Arbutus Biopharma — Investor Presentation (November 2019) on 6ix